BRPI0916230A2 - rna antagonists targeting gli2 - Google Patents

rna antagonists targeting gli2

Info

Publication number
BRPI0916230A2
BRPI0916230A2 BRPI0916230A BRPI0916230A BRPI0916230A2 BR PI0916230 A2 BRPI0916230 A2 BR PI0916230A2 BR PI0916230 A BRPI0916230 A BR PI0916230A BR PI0916230 A BRPI0916230 A BR PI0916230A BR PI0916230 A2 BRPI0916230 A2 BR PI0916230A2
Authority
BR
Brazil
Prior art keywords
gli2
antagonists targeting
rna antagonists
targeting gli2
rna
Prior art date
Application number
BRPI0916230A
Other languages
Portuguese (pt)
Inventor
Hedtjärn Maj
Original Assignee
Enzon Pharmaceuticals Inc
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc, Santaris Pharma As filed Critical Enzon Pharmaceuticals Inc
Priority claimed from PCT/IB2009/006407 external-priority patent/WO2010007522A1/en
Publication of BRPI0916230A2 publication Critical patent/BRPI0916230A2/en

Links

Abstract

"antagonistas de rna que tem como alvo a gli2" a presente invenção refere-se aos compostos de oligômero (oligômeros), que alvejam mrna de gli2 em uma célula, levando a uma reduzida expressão de gli2. a redução de expressão de gli2 é benéfica para o tratamento de determinados distúrbios médicos, como distúrbios hiperproliferativos, como câncer.The present invention relates to oligomer compounds (oligomers) which target gli2 mRNA in a cell, leading to reduced expression of gli2. Gli2 expression reduction is beneficial for the treatment of certain medical disorders such as hyperproliferative disorders such as cancer.

BRPI0916230A 2008-07-15 2009-07-15 rna antagonists targeting gli2 BRPI0916230A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08104754 2008-07-15
US8113508P 2008-07-16 2008-07-16
PCT/IB2009/006407 WO2010007522A1 (en) 2008-07-15 2009-07-15 Rna antagonists targeting gli2

Publications (1)

Publication Number Publication Date
BRPI0916230A2 true BRPI0916230A2 (en) 2019-04-16

Family

ID=67251416

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916230A BRPI0916230A2 (en) 2008-07-15 2009-07-15 rna antagonists targeting gli2

Country Status (1)

Country Link
BR (1) BRPI0916230A2 (en)

Similar Documents

Publication Publication Date Title
MX2010005703A (en) Lna antagonists targeting the androgen receptor.
MX2018012038A (en) Modified rnai agents.
UA115983C2 (en) Dna-pk inhibitors
BR112012030699A2 (en) Methods To Treat Bladder Cancer
MX2010006039A (en) Rna antagonist compounds for the modulation of pik3ca expression.
MX2019002917A (en) Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma.
MD20150043A2 (en) Inhibitors of histone demethylases
BR112015000399A2 (en) pyrazolyl pyrimidine derivatives
CU20110168A7 (en) BENZOFURANILO DERIVATIVES
IN2012DN02081A (en)
CL2009001151A1 (en) Compounds derived from benzomorphane alicyclic carbocyclic acids, preparation procedure, pharmaceutical composition, useful for treating diseases influenced by the inhibition of the enzyme 11beta-hydroxysteroid dehydrogenase, such as metabolic disorders.
MX2009011878A (en) Rna antagonist compounds for the modulation of beta-catenin.
MX346147B (en) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use.
NZ607996A (en) Substituted nucleotide analogs
MY166026A (en) Tetrahydro-pyrido-pyrimidine derivatives
BR112014026801A2 (en) 5 - [[4 - [[morpholin-2-yl] methylamino] -5- (trifluoromethyl) -2-pyridyl] amino] pyrazine-2-carbonitrile and therapeutic uses thereof
UY33246A (en) TIENOPIRIMIDINES CONTAINING CYCLLOQUAL FOR PHARMACEUTICAL COMPOSITIONS
WO2010007522A8 (en) Rna antagonists targeting gli2
BR112014021612A2 (en) compositions and methods for modulating atxn3 expression
MX2015006289A (en) Compositions and methods for modulation of fgfr3 expression.
MX2011009493A (en) Compounds for the treatment of metabolic disorders.
MX337849B (en) Compositions and methods for inhibition of the jak pathway.
MX349550B (en) 1, 7 - diazacarbazoles and their use in the treatment of cancer.
BR112015029504A2 (en) kinase inhibitors
BR112012013918A2 (en) diacyl glycerol acyl transferase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2520 DE 25-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]